BridgeBio Pharma (BBIO) Fundamentals 2026 — Revenue Analysis | SniperIQ
BridgeBio Pharma (BBIO) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BridgeBio Pharma's market cap?
BridgeBio Pharma (BBIO) has a market capitalization of approximately
How profitable is BridgeBio Pharma?
BridgeBio Pharma runs a net profit margin of -125.2%, a gross margin of 93.8%, and an operating margin of -98.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BridgeBio Pharma generate?
BridgeBio Pharma reported revenue of $502M for fiscal year 2025, with net income of -$729M and earnings per share (EPS) of -3.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BridgeBio Pharma pay a dividend?
BridgeBio Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is BridgeBio Pharma financially healthy?
BridgeBio Pharma carries a debt-to-equity ratio of -1.49x and a current ratio of 1.44x, with a market beta of 0.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BridgeBio Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BridgeBio Pharma (BBIO) the key facts are: market cap
Track BridgeBio Pharma's full fundamentals live
Get BridgeBio Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.